Home Cart Sign in  
Chemical Structure| 2230273-76-2 Chemical Structure| 2230273-76-2

Structure of Safimaltib
CAS No.: 2230273-76-2

Chemical Structure| 2230273-76-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Safimaltib (JNJ-67856633) is an orally active, first-class, highly efficient, selective, and allosteric MALT1 protease inhibitor that can halt tumor growth in certain cases.

Synonyms: JNJ-67856633; JNJ-6633

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Safimaltib

CAS No. :2230273-76-2
Formula : C20H11F6N5O2
M.W : 467.32
SMILES Code : O=C(C1=C(C(F)(F)F)N(C2=CC=CC3=C2C=CNC3=O)N=C1)NC4=CC(C(F)(F)F)=NC=C4
Synonyms :
JNJ-67856633; JNJ-6633
MDL No. :MFCD34475932

Safety of Safimaltib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319
Precautionary Statements:P501-P270-P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313-P301+P312+P330

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT03900598 Leukemia, Lymphocytic, Chronic... More >>, B-Cell|Lymphoma, Non-Hodgkin Less << PHASE1 ACTIVE_NOT_RECRUITING 2025-04-30 City of Hope, Duarte, Californ... More >>ia, 91010, United States|University of Nebraska Medical Center, Omaha, Nebraska, 68198, United States|Weill Cornell Medicine, New York, New York, 10021, United States|Icahn School of Medicine at Mount Sinai, New York, New York, 10029, United States|Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States|MD Anderson, Houston, Texas, 77025, United States|Monash Medical Centre, Clayton, 3168, Australia|Peter MacCallum Cancer Centre, Melbourne, 3000, Australia|Linear Clinical Research Ltd, Nedlands, 6009, Australia|Scientia Clinical Research, Randwick, 2031, Australia|The First Affiliated Hospital of NanChang University, Nanchang, 330006, China|Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060, China|Institute of Hematology & Blood Disease Hospital Chinese Academy of Medical Science, Tianjin, 300320, China|The First Affiliated Hospital of Xian Jiaotong University, Xi'an, China|Hopital Claude Huriez, Lille, 59037, France|CHU de Nantes hotel Dieu, Nantes Cedex 1, 44093, France|Institut Curie, PARIS Cedex 5, 75248, France|Groupe Hospitalier Pitie Salpetriere, Paris, 75013, France|Centre hospitalier Lyon-Sud, Pierre Benite, 69495, France|Institut Universitaire du Cancer Toulouse - Oncopole, Toulouse, 31059, France|CHU Bretonneau, Tours Cedex 9, 37044, France|Institut Gustave Roussy, VILLEJUIF Cedex, 94805, France|Universitatsklinikum Munster, Münster, 48149, Germany|Universitatsklinikum Ulm, Ulm, 89081, Germany|Alexandra General Hospital of Athens, Athens, 11528, Greece|Hadassah Medical Center, Jerusalem, 91120, Israel|Sheba Medical Center, Ramat Gan, 74047, Israel|Tel Aviv Sourasky Medical Center, Tel Aviv, 64239, Israel|Azienda Opedaliero-Universitaria Policlinico Sant'orsola Malpighi di Bologna, Bologna, 40138, Italy|ASST Grande Ospedale Metropolitano Niguarda, Milano, 20162, Italy|National Cancer Center Hospital, Chuo Ku, 104 0045, Japan|Tokai University Hospital, Isehara, 259-1193, Japan|National Hospital Organization Nagoya Medical Center, Nagoya-shi, 460-0001, Japan|Okayama University Hospital, Okayama, 700 8558, Japan|The Cancer Institute Hospital of JFCR, Tokyo, 135 8550, Japan|Seoul National University Hospital, Seoul, 03080, Korea, Republic of|Asan Medical Center, Seoul, 05505, Korea, Republic of|Samsung Medical Center, Seoul, 06351, Korea, Republic of|Hosp. Univ. Germans Trias I Pujol, Badalona, 8916, Spain|Hospital de Vall D'Hebron, Barcelona, 08035, Spain|Hosp Univ Fund Jimenez Diaz, Madrid, 28040, Spain|Hosp. Univ. 12 de Octubre, Madrid, 28041, Spain|Clinica Univ. de Navarra, Pamplona, 31008, Spain|Hosp. Quiron Madrid Pozuelo, Pozuelo de Alarcon, 28223, Spain|Hosp Clinico Univ de Salamanca, Salamanca, 37007, Spain|Hosp. Univ. Marques de Valdecilla, Santander, 39008, Spain|St Bartholomew's Hospital, London, EC1A 7BE, United Kingdom Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.14mL

0.43mL

0.21mL

10.70mL

2.14mL

1.07mL

21.40mL

4.28mL

2.14mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
 

Historical Records

Categories